サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：動脈硬化治療薬の世界市場規模調査＆予測：ステージ別、診断別、治療別、投与経路別、エンドユーザー別、流通チャネル別、地域別分析、2023-2030年
市場調査レポート
商品コード
1290509

動脈硬化治療薬の世界市場規模調査＆予測：ステージ別、診断別、治療別、投与経路別、エンドユーザー別、流通チャネル別、地域別分析、2023-2030年

Global Atherosclerosis drugs Market Size study & Forecast, by Stages, by Diagnosis, by Treatment, by Route of Administration, by End-Users, by Distribution Channel and Regional Analysis, 2023-2030
出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
動脈硬化治療薬の世界市場規模調査＆予測：ステージ別、診断別、治療別、投与経路別、エンドユーザー別、流通チャネル別、地域別分析、2023-2030年
出版日: 2023年06月10日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

動脈硬化治療薬の世界市場は、2022年に約27億米ドルと評価され、予測期間2023-2030年には6.16%以上の健全な成長率で成長すると予測されています。

動脈硬化治療薬は、動脈硬化治療および心臓発作、脳卒中、末梢血管疾患などの関連する心血管疾患の治療に使用される医薬品の治療カテゴリです。この市場の成長は、動脈の閉塞を軽減または回避するために、患者がコレステロール低下薬を多く消費していることに起因しています。ますますペースの速いライフスタイルは、年齢層にもかかわらず、動脈硬化のリスクを高める必須栄養素の一般人の通常の食事を枯渇させ、動脈硬化市場の成長率は、そのインフラの改善に役立つ医療費の上昇です。ヘルスケア分野における研究開発は、世界的に効果的な動脈硬化治療薬の生産につながっています。

動脈硬化のリスクを高める、肥満や高コレステロールの有病率の増加は、市場の成長率を押し上げると予測されています。2020年の世界保健機関（WHO）の推計によると、5歳未満の子どものうち4,000万人が過体重または肥満であることが判明しています。脂肪分や糖分を多く含む食品の消費量の増加、多くの仕事が身体的負担を軽減しているという事実がもたらす身体的不動の増加、交通手段の変化、都市化の進展などが、人々の高コレステロール率に寄与する要因となっており、市場の急拡大を牽引しています。さらに、研究開発活動の活発化、eコマースとヘルスケア分野の融合により、動脈硬化治療薬市場に参入する企業にとってオンライン薬局を通じた大きな売上が期待できることも、市場の成長に拍車をかけています。しかし、薬剤の副作用やジェネリック医薬品の利用可能性が、予測期間中の市場成長を抑制する要因になると予想されます。

動脈硬化治療薬の世界市場調査において考慮される主要地域は、アジア太平洋、北米、欧州、ラテンアメリカ、中東・アフリカです。北米は、動脈硬化治療の発生頻度の増加や治療技術の向上により、2022年には最大の市場シェアを占めています。さらに、ヘルスケア支出の増加や重要な主要企業の存在が、この地域の市場開拓を促進すると考えられます。2022年7月に更新された国立慢性疾患予防・健康増進センターの心臓病・脳卒中予防部門によると、米国では34秒に1人が心血管疾患により死亡しています。アジア太平洋は、この地域の高齢者人口の増加や可処分所得水準の上昇により、予測期間中に大きく成長すると予想されています。また、ヘルスケア分野のインフラ整備や政府の取り組みが進んでいることも、同地域での市場拡大を加速させるでしょう。

目次

第1章 エグゼクティブサマリー

  • マーケットスナップショット
  • 世界・セグメント別市場推計・予測、2020-2030年
  • 主な動向
  • 調査手法
  • 調査の前提条件

第2章 動脈硬化治療薬の世界市場の定義と範囲

  • 調査目的
  • 市場の定義と範囲
    • 産業の進化
    • 本調査の対象範囲
  • 調査対象年
  • 通貨換算レート

第3章 動脈硬化治療薬の世界市場力学

  • 動脈硬化治療薬市場の影響分析（2020年～2030年）
    • 市場促進要因
      • ヘルスケアインフラへの投資拡大
      • 老年人口の増加
    • 市場の課題
      • 高コストと低診断率
      • 薬剤の副作用
    • 市場機会
      • 研究開発活動の活発化
      • 政府のイニシアティブは、ヘルスケアサービスやインフラの水準を向上させるために不可欠です

第4章 動脈硬化治療薬の世界市場：産業分析

  • ポーターの5フォースモデル
    • 供給企業の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • ポーターの5フォース影響分析
  • PEST分析
    • 政治的
    • 経済的
    • 社会的
    • 技術的
    • 環境
    • 法律
  • 主な投資機会
  • 主要成功戦略
  • COVID-19影響度分析
  • 破壊的動向
  • 業界専門家の視点
  • アナリストの提言と結論

第5章 動脈硬化治療薬の世界市場：ステージ別

  • 市場スナップショット
  • 動脈硬化治療薬の世界市場：ステージ別、実績 - ポテンシャル分析
  • 動脈硬化治療薬の世界市場ステージ別推定・予測2020-2030
  • 動脈硬化治療薬の市場、サブセグメント別分析
    • 内皮障害と免疫反応
    • ファットストリーク
    • プラーク成長
    • プラーク破裂

第6章 動脈硬化治療薬の世界市場：診断別

  • 市場スナップショット
  • 動脈硬化治療薬の世界市場：診断別、実績 - ポテンシャル分析
  • 動脈硬化治療薬の世界市場、診断別推定・予測2020-2030
  • 動脈硬化治療薬の市場、サブセグメント別分析
    • 足関節上腕血圧計
    • ドップラー超音波
    • 心エコー図
    • 心電図
    • 血液検査
    • その他

第7章 動脈硬化治療薬の世界市場：治療法別

  • 市場スナップショット
  • 動脈硬化治療薬の世界市場：治療別、実績、潜在能力分析
  • 動脈硬化治療薬の世界市場、治療別推定・予測2020-2030
  • 動脈硬化治療薬の市場、サブセグメント別分析
    • 薬物療法
    • 外科治療薬
    • その他

第8章 動脈硬化治療薬の世界市場：投与経路別

  • 市場スナップショット
  • 動脈硬化治療薬の世界市場：投与経路別、実績 - ポテンシャル分析
  • 動脈硬化治療薬の世界市場、投与経路別推定・予測2020-2030
  • 動脈硬化治療薬の市場、サブセグメント別分析
    • 経口剤
    • 非経口剤
    • その他

第9章 動脈硬化治療薬の世界市場：エンドユーザー別

  • 市場スナップショット
  • 動脈硬化治療薬の世界市場：エンドユーザー別実績-ポテンシャル分析
  • 動脈硬化治療薬の世界市場：エンドユーザー別推定・予測2020年～2030年
  • 動脈硬化治療薬の市場、サブセグメント別分析
    • 病院
    • 専門クリニック
    • ホームケア
    • その他

第10章 動脈硬化治療薬の世界市場：流通チャネル別

  • 市場スナップショット
  • 動脈硬化治療薬の世界市場：流通チャネル別、実績-ポテンシャル分析
  • 動脈硬化治療薬の世界市場、流通チャネル別推定・予測2020～2030年
  • 動脈硬化治療薬の市場、サブセグメント別分析
    • 病院薬局
    • 小売薬局
    • オンラインファーマシー
    • その他

第11章 動脈硬化治療薬の世界市場：地域別分析

  • 主要国
  • 主な新興国
  • 動脈硬化治療薬市場、地域別市場スナップショット
  • 北米
    • 米国
      • ステージ別の推定・予測、2020-2030年
      • 診断別の推定・予測、2020-2030年
      • 治療別の推定と予測、2020-2030年
      • 投与経路別の推定と予測、2020-2030年
      • エンドユーザー別内訳の推定と予測、2020-2030年
      • 流通チャネルの内訳の推定と予測、2020-2030年
    • カナダ
  • 欧州動脈硬化治療薬市場スナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋地域の動脈硬化治療薬市場スナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカの動脈硬化治療薬市場スナップショット
    • ブラジル
    • メキシコ
  • 中東・アフリカ地域
    • サウジアラビア
    • 南アフリカ
    • その他中東とアフリカ

第12章 競合情報

  • 主要企業のSWOT分析
  • 主な市場戦略
  • 企業プロファイル
    • F. Hoffmann-La Roche Ltd.
      • 主要情報
      • 概要
      • 財務情報（データの入手が可能な場合のみ）
      • 製品概要
      • 最近の開発状況
    • Mylan N.V.
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi India
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Novartis AG
    • Merck & Co
    • Allergan India Pvt Ltd.
    • AstraZeneca

第13章 調査プロセス

  • 調査プロセス
    • データマイニング
    • 分析
    • 市場推定
    • バリデーション
    • 出版
  • 調査の特徴
  • 調査の前提条件
図表

LIST OF TABLES

  • TABLE 1. Global Atherosclerosis drugs Market, report scope
  • TABLE 2. Global Atherosclerosis drugs Market estimates & forecasts by Region 2020-2030 (USD Billion)
  • TABLE 3. Global Atherosclerosis drugs Market estimates & forecasts by Stages 2020-2030 (USD Billion)
  • TABLE 4. Global Atherosclerosis drugs Market estimates & forecasts by Diagnosis 2020-2030 (USD Billion)
  • TABLE 5. Global Atherosclerosis drugs Market estimates & forecasts by Treatment 2020-2030 (USD Billion)
  • TABLE 6. Global Atherosclerosis drugs Market estimates & forecasts by Route of Administration 2020-2030 (USD Billion)
  • TABLE 7. Global Atherosclerosis drugs Market estimates & forecasts by End-User 2020-2030 (USD Billion)
  • TABLE 8. Global Atherosclerosis drugs Market estimates & forecasts by Distribution Channel 2020-2030 (USD Billion)
  • TABLE 9. Global Atherosclerosis drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 10. Global Atherosclerosis drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 11. Global Atherosclerosis drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 12. Global Atherosclerosis drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 13. Global Atherosclerosis drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 14. Global Atherosclerosis drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 15. Global Atherosclerosis drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 16. Global Atherosclerosis drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 17. Global Atherosclerosis drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 18. Global Atherosclerosis drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 19. U.S. Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 20. U.S. Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 21. U.S. Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 22. Canada Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 23. Canada Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 24. Canada Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 25. UK Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 26. UK Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 27. UK Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 28. Germany Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 29. Germany Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 30. Germany Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 31. France Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 32. France Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 33. France Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 34. Italy Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 35. Italy Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 36. Italy Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 37. Spain Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 38. Spain Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 39. Spain Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 40. RoE Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 41. RoE Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 42. RoE Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 43. China Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 44. China Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 45. China Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 46. India Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 47. India Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 48. India Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 49. Japan Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 50. Japan Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 51. Japan Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 52. South Korea Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 53. South Korea Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 54. South Korea Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 55. Australia Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 56. Australia Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 57. Australia Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 58. RoAPAC Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 59. RoAPAC Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 60. RoAPAC Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 61. Brazil Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 62. Brazil Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 63. Brazil Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 64. Mexico Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 65. Mexico Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 66. Mexico Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 67. RoLA Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 68. RoLA Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 69. RoLA Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 70. Saudi Arabia Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 71. South Africa Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 72. RoMEA Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 73. List of secondary sources, used in the study of global Atherosclerosis drugs Market
  • TABLE 74. List of primary sources, used in the study of global Atherosclerosis drugs Market
  • TABLE 75. Years considered for the study
  • TABLE 76. Exchange rates considered

List of tables and figures are dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Atherosclerosis drugs Market, research methodology
  • FIG 2. Global Atherosclerosis drugs Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Atherosclerosis drugs Market, key trends 2022
  • FIG 5. Global Atherosclerosis drugs Market, growth prospects 2023-2030
  • FIG 6. Global Atherosclerosis drugs Market, porters 5 force model
  • FIG 7. Global Atherosclerosis drugs Market, pest analysis
  • FIG 8. Global Atherosclerosis drugs Market, value chain analysis
  • FIG 9. Global Atherosclerosis drugs Market by segment, 2020 & 2030 (USD Billion)
  • FIG 10. Global Atherosclerosis drugs Market by segment, 2020 & 2030 (USD Billion)
  • FIG 11. Global Atherosclerosis drugs Market by segment, 2020 & 2030 (USD Billion)
  • FIG 12. Global Atherosclerosis drugs Market by segment, 2020 & 2030 (USD Billion)
  • FIG 13. Global Atherosclerosis drugs Market by segment, 2020 & 2030 (USD Billion)
  • FIG 14. Global Atherosclerosis drugs Market, regional snapshot 2020 & 2030
  • FIG 15. North America Atherosclerosis drugs Market 2020 & 2030 (USD Billion)
  • FIG 16. Europe Atherosclerosis drugs Market 2020 & 2030 (USD Billion)
  • FIG 17. Asia pacific Atherosclerosis drugs Market 2020 & 2030 (USD Billion)
  • FIG 18. Latin America Atherosclerosis drugs Market 2020 & 2030 (USD Billion)
  • FIG 19. Middle East & Africa Atherosclerosis drugs Market 2020 & 2030 (USD Billion)

List of tables and figures are dummy in nature, final lists may vary in the final deliverable

目次

Global Atherosclerosis drugs Market is valued approximately at USD 2.7 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 6.16% over the forecast period 2023-2030. Atherosclerosis drugs is a therapeutic category of medications used for the treatment of atherosclerosis and related cardiovascular diseases such as heart attacks, strokes, and peripheral vascular disease. This market growth is attributed to the high consumption of cholesterol-lowering drugs by patients to reduce or avoid blockages in arteries. The increasingly fast-paced lifestyle has depleted the ordinary person's usual diet of essential nutrients that increases the risk of atherosclerosis, despite the age group and the growth rate of atherosclerosis market is the rising healthcare expenditure which helps in improving its infrastructure. The research and development in the healthcare sector have led to the production of effective atherosclerosis drugs globally.

Increasing the risk of atherosclerosis, the increased prevalence of obesity and high cholesterol is predicted to boost the market's growth rate. According to estimates from the World Health Organisation (WHO) in 2020, 40 million children under the age of five were overweight or obese. Increased consumption of food high in fat and sugar as well as an increase in physical immobility brought on by the fact that many jobs are becoming less physically demanding, changing transportation options and growing urbanization are the factors that contributes to high cholesterol rates in people that are driving the market's rapid expansion. Moreover, the market's growth is fueled by an increase in the number of research and development activities also the integration of e-Commerce and the healthcare sector will generate considerable sales potential through online pharmacies for companies in the atherosclerosis medicines market. However, Side effects of drugs and the availability of generic products are the factors expected to restrain the market growth during the forecast period.

The key regions considered for the Global Atherosclerosis drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 holding the largest market share owing to the increased frequency of atherosclerosis and technical improvement in the treatment in this region. Furthermore, increased healthcare expenditure and the presence of significant key players would drive the market development rate in this area. According to the National Centre for Chronic Disease Prevention and Health Promotion's Division for Heart Disease and Stroke Prevention, which was updated in July 2022, one person dies from cardiovascular disease every 34 seconds in the United States. Asia Pacific is expected to grow significantly during the forecast period, owing to the growing elderly population in this area and the rising level of disposable income. Additionally, the expansion of the healthcare sector's infrastructure and growing government efforts will accelerate the market's expansion in this area.

Major market player included in this report are:

  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Merck & Co
  • Allergan Plc
  • AstraZeneca

Recent Developments in the Market:

  • In September 2022, Novo Nordisk has entered into a new strategic cooperation with Microsoft to accelerate medication research and development via the use of big data and artificial intelligence (AI). The team will employ artificial intelligence to construct models that can predict a person's risk of getting atherosclerosis or arterial plaque development. The researchers will also look for new atherosclerosis targets and indicators.
  • In August 2022, AstraZeneca and Merck, known as MSD outside the United States and Canada, announced that the European Commission (EC) has approved LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2 mutations (gBRCAm) and HER2-negative high-risk early breast cancer who have previously received neoadjuvant or adjuvant chemotherapy.

Global Atherosclerosis drugs Market Report Scope:

  • Historical Data: 2020 - 2021
  • Base Year for Estimation: 2022
  • Forecast period: 2023-2030
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Stages, Diagnosis, Treatment, Route of Administration, End-Users, Distribution Channel, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*
  • The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Stages:

  • Endothelial Damage and Immune Response
  • Fatty Streak
  • Plaque Growth
  • Plaque Rupture

By Diagnosis:

  • Ankle-brachial Index
  • Doppler Ultrasound
  • Echocardiogram
  • Electrocardiogram
  • Blood Tests
  • Others

By Treatment:

  • Medication
  • Surgery
  • Others

By Route of Administration:

  • Oral,
  • Parenteral
  • Others

By End-Users:

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1. Atherosclerosis drugs Market, by region, 2020-2030 (USD Billion)
    • 1.2.2. Atherosclerosis drugs Market, by Stages, 2020-2030 (USD Billion)
    • 1.2.3. Atherosclerosis drugs Market, by Diagnosis, 2020-2030 (USD Billion)
    • 1.2.4. Atherosclerosis drugs Market, by Treatment, 2020-2030 (USD Billion)
    • 1.2.5. Atherosclerosis drugs Market, by Route of Administration, 2020-2030 (USD Billion)
    • 1.2.6. Atherosclerosis drugs Market, by End-User, 2020-2030 (USD Billion)
    • 1.2.7. Atherosclerosis drugs Market, by Distribution Channel, 2020-2030 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Atherosclerosis drugs Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Atherosclerosis drugs Market Dynamics

  • 3.1. Atherosclerosis drugs Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing investment in healthcare infrastructure
      • 3.1.1.2. Growing Geriatric Population
    • 3.1.2. Market Challenges
      • 3.1.2.1. High Cost and low diagnostic rates
      • 3.1.2.2. Side effects of drugs
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Increase in the number of research and development activities
      • 3.1.3.2. Government initiatives have been essential in raising the standard of healthcare services and infrastructure

Chapter 4. Global Atherosclerosis drugs Market: Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economic
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Atherosclerosis drugs Market, by Stages

  • 5.1. Market Snapshot
  • 5.2. Global Atherosclerosis drugs Market by Stages, Performance - Potential Analysis
  • 5.3. Global Atherosclerosis drugs Market Estimates & Forecasts by Stages 2020-2030 (USD Billion)
  • 5.4. Atherosclerosis drugs Market, Sub Segment Analysis
    • 5.4.1. Endothelial Damage and Immune Response
    • 5.4.2. Fatty Streak
    • 5.4.3. Plaque Growth
    • 5.4.4. Plaque Rupture

Chapter 6. Global Atherosclerosis drugs Market, by Diagnosis

  • 6.1. Market Snapshot
  • 6.2. Global Atherosclerosis drugs Market by Diagnosis, Performance - Potential Analysis
  • 6.3. Global Atherosclerosis drugs Market Estimates & Forecasts by Diagnosis 2020-2030 (USD Billion)
  • 6.4. Atherosclerosis drugs Market, Sub Segment Analysis
    • 6.4.1. Ankle-brachial Index
    • 6.4.2. Doppler Ultrasound
    • 6.4.3. Echocardiogram
    • 6.4.4. Electrocardiogram
    • 6.4.5. Blood Tests
    • 6.4.6. Others

Chapter 7. Global Atherosclerosis drugs Market, by Treatment

  • 7.1. Market Snapshot
  • 7.2. Global Atherosclerosis drugs Market by Treatment, Performance - Potential Analysis
  • 7.3. Global Atherosclerosis drugs Market Estimates & Forecasts by Treatment 2020-2030 (USD Billion)
  • 7.4. Atherosclerosis drugs Market, Sub Segment Analysis
    • 7.4.1. Medication
    • 7.4.2. Surgery
    • 7.4.3. Others

Chapter 8. Global Atherosclerosis drugs Market, by Route of Administration

  • 8.1. Market Snapshot
  • 8.2. Global Atherosclerosis drugs Market by Route of Administration, Performance - Potential Analysis
  • 8.3. Global Atherosclerosis drugs Market Estimates & Forecasts by Route of Administration 2020-2030 (USD Billion)
  • 8.4. Atherosclerosis drugs Market, Sub Segment Analysis
    • 8.4.1. Oral
    • 8.4.2. Parenteral
    • 8.4.3. Others

Chapter 9. Global Atherosclerosis drugs Market, by End-User

  • 9.1. Market Snapshot
  • 9.2. Global Atherosclerosis drugs Market by End-User, Performance - Potential Analysis
  • 9.3. Global Atherosclerosis drugs Market Estimates & Forecasts by End-User2020-2030 (USD Billion)
  • 9.4. Atherosclerosis drugs Market, Sub Segment Analysis
    • 9.4.1. Hospitals
    • 9.4.2. Specialty Clinics
    • 9.4.3. Homecare
    • 9.4.4. Others

Chapter 10. Global Atherosclerosis drugs Market, by Distribution Channel

  • 10.1. Market Snapshot
  • 10.2. Global Atherosclerosis drugs Market by Distribution Channel, Performance - Potential Analysis
  • 10.3. Global Atherosclerosis drugs Market Estimates & Forecasts by Distribution Channel 2020-2030 (USD Billion)
  • 10.4. Atherosclerosis drugs Market, Sub Segment Analysis
    • 10.4.1. Hospital Pharmacy
    • 10.4.2. Retail Pharmacy
    • 10.4.3. Online Pharmacy
    • 10.4.4. Others

Chapter 11. Global Atherosclerosis drugs Market, Regional Analysis

  • 11.1. Top Leading Countries
  • 11.2. Top Emerging Countries
  • 11.3. Atherosclerosis drugs Market, Regional Market Snapshot
  • 11.4. North America Atherosclerosis Drugs Market
    • 11.4.1. U.S. Atherosclerosis drugs Market
      • 11.4.1.1. Stages breakdown estimates & forecasts, 2020-2030
      • 11.4.1.2. Diagnosis breakdown estimates & forecasts, 2020-2030
      • 11.4.1.3. Treatment breakdown estimates & forecasts, 2020-2030
      • 11.4.1.4. Route of Administration breakdown estimates & forecasts, 2020-2030
      • 11.4.1.5. End-User breakdown estimates & forecasts, 2020-2030
      • 11.4.1.6. Distribution Channel breakdown estimates & forecasts, 2020-2030
    • 11.4.2. Canada Atherosclerosis drugs Market
  • 11.5. Europe Atherosclerosis drugs Market Snapshot
    • 11.5.1. U.K. Atherosclerosis drugs Market
    • 11.5.2. Germany Atherosclerosis drugs Market
    • 11.5.3. France Atherosclerosis drugs Market
    • 11.5.4. Spain Atherosclerosis drugs Market
    • 11.5.5. Italy Atherosclerosis drugs Market
    • 11.5.6. Rest of Europe Atherosclerosis drugs Market
  • 11.6. Asia-Pacific Atherosclerosis drugs Market Snapshot
    • 11.6.1. China Atherosclerosis drugs Market
    • 11.6.2. India Atherosclerosis drugs Market
    • 11.6.3. Japan Atherosclerosis drugs Market
    • 11.6.4. Australia Atherosclerosis drugs Market
    • 11.6.5. South Korea Atherosclerosis drugs Market
    • 11.6.6. Rest of Asia Pacific Atherosclerosis Drugs Market
  • 11.7. Latin America Atherosclerosis drugs Market Snapshot
    • 11.7.1. Brazil Atherosclerosis drugs Market
    • 11.7.2. Mexico Atherosclerosis drugs Market
  • 11.8. Middle East & Africa Atherosclerosis drugs Market
    • 11.8.1. Saudi Arabia Atherosclerosis drugs Market
    • 11.8.2. South Africa Atherosclerosis drugs Market
    • 11.8.3. Rest of Middle East & Africa Atherosclerosis drugs Market

Chapter 12. Competitive Intelligence

  • 12.1. Key Company SWOT Analysis
    • 12.1.1. Company 1
    • 12.1.2. Company 2
    • 12.1.3. Company 3
  • 12.2. Top Market Strategies
  • 12.3. Company Profiles
    • 12.3.1. F. Hoffmann-La Roche Ltd.
      • 12.3.1.1. Key Information
      • 12.3.1.2. Overview
      • 12.3.1.3. Financial (Subject to Data Availability)
      • 12.3.1.4. Product Summary
      • 12.3.1.5. Recent Developments
    • 12.3.2. Mylan N.V.
    • 12.3.3. Teva Pharmaceutical Industries Ltd.
    • 12.3.4. Sanofi India
    • 12.3.5. Pfizer Inc.
    • 12.3.6. GlaxoSmithKline plc
    • 12.3.7. Novartis AG
    • 12.3.8. Merck & Co
    • 12.3.9. Allergan India Pvt Ltd.
    • 12.3.10. AstraZeneca

Chapter 13. Research Process

  • 13.1. Research Process
    • 13.1.1. Data Mining
    • 13.1.2. Analysis
    • 13.1.3. Market Estimation
    • 13.1.4. Validation
    • 13.1.5. Publishing
  • 13.2. Research Attributes
  • 13.3. Research Assumption